(Q43036910)

12 November 2017

Hepatitis C virus infection in renal failure patients in the absence of anti-hepatitis C virus antibodies (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

Hanuka N

1

1 reference

12 November 2017

Sikuler E

2

1 reference

12 November 2017

Tovbin D

3

1 reference

12 November 2017

Mostoslavsky M

4

1 reference

12 November 2017

Hausman M

5

1 reference

12 November 2017

Orgel M

6

1 reference

12 November 2017

Yaari A

7

1 reference

12 November 2017

Shemer-Avni Y

8

1 reference

12 November 2017

1 March 2002

1 reference

Journal of Viral Hepatitis

12 November 2017

1 reference

12 November 2017

9

1 reference

12 November 2017

2

1 reference

12 November 2017

141-145

1 reference

High prevalence of and risk factors for hepatitis C in haemodialysis patients in Saudi Arabia: a need for new dialysis strategies

12 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00332.X

Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00332.X

Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: significance and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00332.X

Detection of de novo hepatitis C virus infection by polymerase chain reaction in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00332.X

High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. Copenhagen Dialysis HCV Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00332.X

Prevalence of anti-HCV and HCV viremia in hemodialysis patients in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00332.X

Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00332.X

Absence of HCV viraemia in anti-HCV-negative haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00332.X

Viral heterogeneity of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00332.X

Sensitivity of serological assays to identify blood donors with hepatitis C viraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00332.X

Hepatitis C virus infection and genotypes in Southern Israel and the Gaza Strip

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00332.X

Hepatitis C virus in the haemodialysis units: novel insights by new techniques?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00332.X

Serial quantitative analysis of serum hepatitis C virus RNA level in patients with acute and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00332.X

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00332.X

Destruction of hepatitis C virus particles by haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00332.X

Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00332.X

10.1046/J.1365-2893.2002.00332.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference